Managing Hypertriglyceridemia with Olezarsen, an Oligonucleotide Targeting Apolipoprotein C-III mRNA
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 22nd, 2025
|
Apolipoprotein C-III (APOC3) inhibits triglyceride clearance by interfering with lipoprotein lipase activity. Olezarsen, an antisense oligonucleotide, targets and neutralizes APOC3 mRNA to enhance triglyceride metabolism. Supported by Ionis Pharmaceuticals, a study was conducted to evaluate the efficacy of olezarsen in managing hypertriglyceridemia.
This phase 3 clinical trial enrolled 1,349 participants with a median age of 63 years who had moderate hypertriglyceridemia and an elevated risk of cardiovascular disease. At baseline, the median triglyceride level was approximately 244 mg/dL, and the LDL cholesterol level averaged 87 mg/dL. Most participants (80.5%) were receiving statins, while about 20% were also treated with ezetimibe, fibrates, or omega-3 fatty acids.
Participants were randomly assigned to receive monthly subcutaneous injections of either placebo or olezarsen at doses of 50 mg or 80 mg. After six months, olezarsen treatment led to a significant 65% reduction in triglyceride levels compared with placebo. This improvement was associated with a marked reduction in APOC3 concentrations and a corresponding increase in HDL cholesterol levels. Both dosage groups demonstrated comparable efficacy, although the 80 mg dose showed a slightly higher, but not statistically significant, incidence of adverse events. Despite these promising findings, longer-term studies in more diverse populations are warranted to confirm efficacy and safety.
This phase 3 clinical trial enrolled 1,349 participants with a median age of 63 years who had moderate hypertriglyceridemia and an elevated risk of cardiovascular disease. At baseline, the median triglyceride level was approximately 244 mg/dL, and the LDL cholesterol level averaged 87 mg/dL. Most participants (80.5%) were receiving statins, while about 20% were also treated with ezetimibe, fibrates, or omega-3 fatty acids.
Participants were randomly assigned to receive monthly subcutaneous injections of either placebo or olezarsen at doses of 50 mg or 80 mg. After six months, olezarsen treatment led to a significant 65% reduction in triglyceride levels compared with placebo. This improvement was associated with a marked reduction in APOC3 concentrations and a corresponding increase in HDL cholesterol levels. Both dosage groups demonstrated comparable efficacy, although the 80 mg dose showed a slightly higher, but not statistically significant, incidence of adverse events. Despite these promising findings, longer-term studies in more diverse populations are warranted to confirm efficacy and safety.